TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose in a Phase 1 clinical study. The treatment also showed a potential for effectiveness, with half of those who finished the trial achieving stable disease for several months. As such, TTC-352 may prove to be “a safe and tolerable alternative to chemotherapy” for patients no longer able…
You must be logged in to read/download the full post.
The post TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds appeared first on BioNewsFeeds.